Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy

Nilotinib is a highly selective Bcr-Abl inhibitor approved for imatinib-resistant chronic myeloid leukemia (CML). Nilotinib and dasatinib, a multi-targeted kinase inhibitor also approved for second line therapy in CML, have different patterns of kinase selectivity, pharmacokinetics, and cell uptake...

Full beskrivning

Sparad:
Bibliografiska uppgifter
Huvudupphovsmän: Giles, Francis J., Abruzzese, Elisabetta, Rosti, Gianantonio, Kim, Dong-Wook, Bhatia, Ravi, Bosly, Andre, Goldberg, Stuart, Kam, Grace L.S., Jagasia, Madan, Mendrek, Wlodzimierz, Fischer, Thomas, Facon, Thierry, Dünzinger, Ulrich, Marin, David, Shou, Yaping, Gallagher, Neil J., Larson, Richard A., Mahon, Francois-Xavier, Baccarani, Michele, Cortes, Jorge, Kantarjian, Hagop M.
Materialtyp: Artigo
Språk:Inglês
Publicerad: 2010
Ämnen:
Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC3078756/
https://ncbi.nlm.nih.gov/pubmed/20520639
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/leu.2010.110
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk